Skip to content
Tenfell
Awarded contract
Published 03 Mar 2026

Oncotype DX Breast Cancer Testing

East Sussex Healthcare NHS Trust · United Kingdom

Key facts

Contract value
£272,700
Awarded
02 Mar 2026
Contract starts
31 Mar 2026
Contract ends
31 Mar 2027
Procedure
Call-off from a framework agreement (framework)
Buyer type
Health

Awarded to

SupplierValue
Exact Sciences UK Ltd£272,700

Description

Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.

Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.

Categories (CPV)

Similar open tenders

About East Sussex Healthcare NHS Trust

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on Contracts Finder (Open Government Licence v3.0). Always read the original notice before responding.